Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NEKTAR THERAPEUTICS NKTR

Healthcare
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in immunology and oncology. In oncology, it is focused on developing medicines based on targeting biological pathways that... see more

Recent & Breaking News (NDAQ:NKTR)

16 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  October 19, 2016

Nektar Therapeutics Prices Public Offering of Shares of Common Stock

PR Newswire October 19, 2016

Nektar Therapeutics Announces Public Offering of Shares of Common Stock

PR Newswire October 17, 2016

Nektar Therapeutics to Host Investor & Analyst Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb

PR Newswire September 27, 2016

Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214

Business Wire September 27, 2016

Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics

PR Newswire June 23, 2016

Preclinical Data Presented at ASCO 2016 Annual Meeting Demonstrate that Single-Agent NKTR-214 Produces a Large Increase in Tumor-Infiltrating Lymphocytes to Provide Durable Anti-Tumor Activity

PR Newswire June 6, 2016

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the Jefferies 2016 Global Healthcare Conference in New York City

PR Newswire June 2, 2016

Nektar Therapeutics Announces Executive Management Promotions

PR Newswire June 2, 2016

Nektar Therapeutics and Daiichi Sankyo Europe GmbH Sign European Licensing Agreement for ONZEALD™ (etirinotecan pegol), an Investigational Drug Candidate Being Developed to Treat Patients with Advanced Breast Cancer and Brain Metastases

PR Newswire June 1, 2016

Nektar Therapeutics Reports Financial Results for the First Quarter of 2016

PR Newswire May 3, 2016

Nektar to Announce Financial Results for the First Quarter 2016 on Tuesday, May 3, 2016, After Close of U.S.-Based Financial Markets

PR Newswire April 28, 2016

Preclinical Data Presented at AACR Demonstrate that Combining NKTR-214 with Checkpoint Blockade is Superior to Dual Checkpoint Inhibition in Increasing Clonality of the T Cell Receptor (TCR) Repertoire and T Cell Tumor Infiltration

PR Newswire April 18, 2016

Nektar Therapeutics to Present at Cowen and Company's 36th Annual Health Care Conference in Boston, MA

PR Newswire March 3, 2016

Nektar Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results

PR Newswire March 1, 2016

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2015 on Tuesday, March 1, 2016, After Close of U.S.-Based Financial Markets

PR Newswire February 26, 2016

Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research

PR Newswire February 1, 2016

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire January 6, 2016

Identifying Opportunity, Placing Risk -- Analyst Notes on Cara Therapeutics, Sigma Designs, Pep Boys - Manny Moe and Jack and Nektar Therapeutics

Accesswire December 21, 2015

Baxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age

Business Wire December 21, 2015